"During our meeting, she relayed anecdotal stories about the remarkable
benefits of eteplirsen in many of the 12 subjects in the eteplirsen study including many
that cannot be captured by the six-minute walk test in young children, including balance,
fine motor skills, higher energy, new motor skills, as well as cardiac and cognitive
benefits. ... Our meeting left us more optimistic regarding the possibility of an accelerated approval
based on medical urgency, safety profile, FDA mandate to speed access to lifesaving
therapies and likelihood that the FDA has data from competitor Prosensa's first placebo
controlled study ... we assign a one-third chance of an accelerated
approval ahead of meeting minutes which we expect by the end of April ... We believe shares of
SRPT are a good investment regardless of the outcome next month because we believe
the drug will ultimately be approved."
IMO, most important words:
"MANY OF THE 12 SUBJECTS"
this bodes quite well for the impending test results